| Literature DB >> 26363100 |
Mathieu Métifiot1, Samir Amrane2, Jean-Louis Mergny3, Marie-Line Andreola4.
Abstract
During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for other applications. AS1411 is a nucleolin-targeting aptamer that underwent phase II clinical trials as anticancer agent. Here, we show that AS1411 exhibits extremely potent antiviral activity and is therefore an attractive new lead as anti-HIV agent.Entities:
Keywords: Anticancer; Antiviral; G-quadruplexes; Nucleolin; Zintevir
Mesh:
Substances:
Year: 2015 PMID: 26363100 DOI: 10.1016/j.biochi.2015.09.009
Source DB: PubMed Journal: Biochimie ISSN: 0300-9084 Impact factor: 4.079